Ten patient case study series: across an integrated care board with a novel new advanced wound dressing with Bioactive Microfibre Gelling (BMG) technology leading to formulary application


Ulceration of the lower limbs results in painful, often debilitating leg wounds that can have a profound effect on patients physical, social, and psychological wellbeing.

It is estimated that the UK spends nearly £2bn each year managing lower limb ulceration. NHS England has highlighted the care patients receive is often sub-optimal and unwarranted variation results in higher costs and longer healing times. Non-healing rates are both common and costly, adding to burden on patients and the healthcare system. Prevalence of leg ulceration is higher in older age groups so as our population ages the problem is likely to increase. (1)

Our integrated care board covers six boroughs, with our trust setting the budget for planning and monitoring most of the health services in the region. Our role is to ensure patients benefit from convenient and high quality healthcare whenever patients are in need. Our leg ulcer service sees approximately 50 patients a week. We receive referrals from all health care professionals, with the majority being from primary care, for patients suffering with recurrent non healing leg ulcers.

In March 2022, an advanced wound dressing with Bioactive Microfibre Gelling (BMG) technology (MaxioCel) was launched in the UK. As a team we were interested to evaluate the clinical impact this dressing could have across our clinical workload.


Following trust guidelines and gaining patient consent, ten patients were enrolled in the evaluation. Each week, over a four week period, the wounds were assessed and progression recorded.


Over a 4 week evaluation period, clinicians noted:

  • Healing trajectory was described as “excellent”, improved healing rates were seen within just the first few dressing changes
  • Significant reduction in pain, exudate and wound size
  • Improved wound bed and periwound skin
  • Facilitated earlier debridement and biofilm removal
  • Haemostatic ability of dressing was exceptional
  • Reduction in pain facilitated commencement of compression therapy in two patients, who previously were unable to tolerate compression.

MaxioCel kept infection at bay meaning no further antibiotics or silver dressings were required.


Multidisciplinary management of patients with chronic ulcers is crucial and should include cost analysis. Data collectionsupports not only improved wound management objectives but reduced visits improved quality of life to support an application for formulary status. We will go on to publish the complete findings of this ten patient evaluation in the coming months, in order to share best practice.

To see the full poster, presented at Wound Care Today 2023, including more details on the case study highlighted, download below.

Download PDF



References Atkin L (2019) Venous leg ulcer prevention 1: identifying patients who are at risk. Nursing Times [online issue]; 115: 6, 24-28.